Utilizing Augmented Intelligence to Drive Optimal Decisions Throughout the Specialty and Rare Disease Product Lifecycle
By: Dan Fisher, Principal, IPM.ai
Life sciences and healthcare companies that set out to pioneer...
A New Reference Model for Clinical Study Recruitment
By: Dan Fisher, Principal, IPM.ai
Conventional clinical study recruitment methods for rare diseases...
Real Chemistry's IPM.ai Expands Partnership with Datavant
San Francisco – Aug. 19, 2021 – Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and...
IPM.ai's Clinical Trial Recruitment Solution Featured in MM&M
By: Dan Fisher, Principal, IPM.ai
Allison Rhee of MM&M reports on IPM.ai's answer to patient...
IPM.ai Accelerates the Clinical Study and Commercialization of Precision Medicine
Targeted Approach Optimizes Clinical Study Recruitment of Medically-Eligible Patients Affected by...
Using Non-Traditional Data to Unlock Disease Insights & Improve Outcomes
By: Dan Fisher, Principal, IPM.ai
Though it’s not often discussed, the most difficult aspect of...
IPM.ai and Momenta at the 62nd Annual ASH Meeting
Our own Julie Gubitosa and Graham Jones accompanied by Keith R. McCrae, MD of the Cleveland Clinic...
Using ML and AI to Infer HCP Specialties
By: Dan Fisher, Principal, IPM.ai
Specialty Physician Identification: Your Best Targets Could Be...
Swoop Partners with IPM.ai for Pharmaceutical Ad Optimization
Real World Data and Social Determinants of Health can now be used for precision cross-channel...